Education
About Us
Working with TipRanks
Follow Us
NextCell Pharma AB (SE:NXTCL)
:NXTCL
NXTCL Stock Chart & Stats
kr0.92
kr0.02(0.56%)
At close: 4:00 PM EST
kr0.92
kr0.02(0.56%)
Day’s Range― - ―
52-Week Rangekr0.69 - kr3.84
Previous CloseN/A
Volume77.06K
Average Volume (3M)173.93K
Market Cap
kr100.70M
Enterprise ValueN/A
Total Cash (Recent Filing)kr16.71M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Jan 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding111,392,960
10 Day Avg. Volume200,624
30 Day Avg. Volume173,931
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NXTCL FAQ
What was NextCell Pharma AB’s price range in the past 12 months?
NextCell Pharma AB lowest stock price was kr0.69 and its highest was kr3.84 in the past 12 months.
What is NextCell Pharma AB’s market cap?
NextCell Pharma AB’s market cap is kr100.70M.
When is NextCell Pharma AB’s upcoming earnings report date?
NextCell Pharma AB’s upcoming earnings report date is Jan 22, 2026 which is in 80 days.
How were NextCell Pharma AB’s earnings last quarter?
NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -kr0.079 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.021.
Is NextCell Pharma AB overvalued?
According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued.
Does NextCell Pharma AB pay dividends?
NextCell Pharma AB does not currently pay dividends.
What is NextCell Pharma AB’s EPS estimate?
NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCell Pharma AB have?
NextCell Pharma AB has 111,392,960 shares outstanding.
What happened to NextCell Pharma AB’s price movement after its last earnings report?
NextCell Pharma AB reported an EPS of -kr0.079 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 0.787%.
Which hedge fund is a major shareholder of NextCell Pharma AB?
Currently, no hedge funds are holding shares in SE:NXTCL
Company Description
NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Biovica International AB Class B
―
Modus Therapeutics Holding AB
―